Latest News

01/11/2018

Genoscience Pharma to present data at ASCO-GI_18th-20th January, San Francisco, CA-USA

Background: Hepatocellular carcinoma (HCC) is the third cause of cancer-related death. GNS561 (Genoscience Pharma, France) is a...

04/02/2017

Genoscience Pharma to present data at the AACR Annual meeting 2017- Washigton, D.C. (Abstract n°1/2)

Abstract: Background: Hepatocellular carcinoma (HCC) remains a major health problem, often diagnosed atlate stages with...

03/16/2017

Genoscience Pharma to present data at the 38th EORTC-PAMM Winter meeting_16th-18th March, Split, Croatia

Background: In spite of wide application of sorafenib for hepatocellular carcinoma (HCC) treatment, and systemic chemotherapy...

10/31/2016

Genoscience Pharma to present data on its promising candidate GNS561 at the Liver meeting 2016- AASLD

Abstract: Background: In spite of successful approval and wide application of sorafenib, the prognosis for patients with...

06/03/2016

Genoscience Pharma to present data on its most promising candidate GNS561 at the 2016 ASCO Annual Meeting

Abstract: In spite of successful approval and wide application of sorafenib, the prognosis for patients with advanced...

07/30/2015

Genoscience Pharma to present data on its most promising candidate GNS561 at the Liver meeting 2015- AASLD

Abstract: Background: In spite of successful approval and wide application of sorafenib, the prognosis for patients with...

09/19/2014

26th EORTC-NCI-AACR SYMPOSIUM

Abstract: Despite efforts to understanding and treat acute myeloid leukemia (AML), there remains a need to more comprehensive...

View all

Mission

Our mission statement: Changing the cancer landscape To build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet...